ARCT News and Press, Arcturus Therapeutics Ltd. From 11/14/23

Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial Enrollment initiated in...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Arcturus Therapeutics Holdings Inc. (ARCT) is expected to report $-1.79 for Q3 2023

2023-11-06 12:15:35 ET More on Arcturus Therapeutics Arcturus: Interim Readout Of Rare Disease Data In Coming Months Arcturus, CSL granted EU review for COVID vaccine Seeking Alpha’s Quant Rating on Arcturus Therapeutics For further details see: Ar...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...

$165 million in manufacturing grants awarded to ARCALIS by the Japanese government Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infect...

2023-10-02 12:28:56 ET More on BioNTech BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript Updated COVID boosters to divide America Pfizer...

2023-09-26 12:37:33 ET More on Arcturus Therapeutics Arcturus: mRNA Therapies For Rare Diseases Accelerate Towards Proof Of Concept Arcturus, CSL granted EU review for COVID vaccine Arcturus Therapeutics' joint venture, ARCALIS bags $115M from Japanese government ...

CF Foundation Increases Financial Commitment to ~$25 Million Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines ...